Search
From London: Spur Therapeutics is in a phase 3 for its gene therapy for Gaucher Disease - using a unique construct that allows them to have a lower dose than other gene therapies
CEO Michael Parini describes the science behind how Spur's gene therapies have two key differences compared to others, including a proprietary capsid. He discusses phase 1/2 data that has already been announced, and how he thinks about the phase 3.
Mar 19
Stevenage, UK based Spur Therapeutics is readying to take its gene therapy for Gaucher disease into phase 3
CEO Michael Parini describes how clinical results Spur has seen to date in six patients, with more data to come later this year, has...
Jul 17, 2024
.png){kind=logo}
